NCT07021495 2025-08-19
SKINERGY
Leiden University Medical Center
Recruiting
Clinical Trials
13 trialsNCT03721172 2024-05-29
ADVANCE
Amgen
Phase 3 Completed
NCT02811783 2022-10-28
Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL
Elorac, Inc.
Phase 3 Terminated
NCT01815424 2019-04-16
A Study Evaluating The Efficacy And Safety Of CP-690,550 In Asian Subjects With Moderate To Severe Plaque Psoriasis
Pfizer
Phase 3 Completed
NCT01186744 2018-12-26
A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Pfizer
Phase 3 Completed
NCT01241591 2018-12-26
A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Pfizer
Phase 3 Completed
NCT03340155 2017-11-13
BioUV2017
Medical University of Graz
Phase NA Unknown
NCT01625455 2017-05-10
Effect of Neurokinin-1 Receptor (NK1R) Antagonism on Pruritus in Patients With Sezary Syndrome
Vanderbilt University Medical Center
Phase 4 Terminated
NCT01831466 2015-11-25
Tofacitinib Ointment For Chronic Plaque Psoriasis
Pfizer
Phase 2 Completed
NCT01801670 2015-01-27
Impact of Vorinostat on Pruritus Signaling Pathways - Merck Study
Boston University
Withdrawn
NCT01276639 2014-09-19
A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis
Pfizer
Phase 3 Completed
NCT01309737 2014-09-19
A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
Pfizer
Phase 3 Completed
NCT00863395 2014-03-31
CTCL
University of Minnesota
Phase 1/2 Terminated